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ABSTRACT
Age-related skeletal muscle sarcopenia is linked with increases in falls, fractures, and death
and therefore has important socioeconomic consequences. The molecular mechanisms con-
trolling age-related muscle loss in humans are not well understood, but are likely to involve
multiple signaling pathways. This study investigated the regulation of several genes and pro-
teins involved in the activation of key signaling pathways promoting muscle hypertrophy,
including GH/STAT5, IGF-1/Akt/GSK-3/4E-BP1, and muscle atrophy, including TNF/
SOCS-3 and Akt/FKHR/atrogene, in muscle biopsies from 13 young (20  0.2 years) and 16
older (70  0.3 years) males. In the older males compared to the young subjects, muscle fiber
cross-sectional area was reduced by 40–45% in the type II muscle fibers. TNF and SOCS-3
were increased by 2.8 and 1.5 fold, respectively. Growth hormone receptor protein (GHR) and
IGF-1 mRNA were decreased by 45%. Total Akt, but not phosphorylated Akt, was increased
by 2.5 fold, which corresponded to a 30% reduction in the efficiency of Akt phosphorylation
in the older subjects. Phosphorylated and total GSK-3 were increased by 1.5 and 1.8 fold,
respectively, while 4E-BP1 levels were not changed. Nuclear FKHR and FKHRL1 were de-
creased by 73 and 50%, respectively, with no changes in their atrophy target genes, atrogin-1
and MuRF1. Myostatin mRNA and protein levels were significantly elevated by 2 and 1.4
fold. Human sarcopenia may be linked to a reduction in the activity or sensitivity of anabolic
signaling proteins such as GHR, IGF-1, and Akt. TNF, SOCS-3, and myostatin are potential
candidates influencing this anabolic perturbation.
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INTRODUCTION
SARCOPENIA IS THE GENERAL TERM for a reduc-tion in muscle quality and function due to
aging. This can be seen by an increase in mus-
cle atrophy, common in type II fibers,1 which
is related to the reduction of maximal volun-
tary strength.2–4 The impairment of muscle de-
velopment and function with age tends to ac-
celerate after the age of 50 years5 and is linked
with increases in falls and fractures, as well as
a decreased capacity to recover from such in-
juries.6 Sarcopenia has an important socioeco-
nomic consequence as falls are a major source
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of morbidity and mortality in the increasing
population of the elderly.7
The molecular mechanisms controlling age-
related skeletal muscle atrophy are not well un-
derstood and is likely to involve multiple cell
signaling pathways controlling both protein
synthesis and degradation. Growth hormone
(GH) plays a key role in muscle development.8
Much of the anabolic effects of GH is mediated
via insulin-like growth factor-1 (IGF-1). IGF-1
gene transcription is controlled by GH9 via a
Janus kinase-2 (JAK2)/signal transducer and
activator of transcription-5b (STAT5b) signal-
ing pathway.10,11 In aging human skeletal mus-
cle, a reduction in IGF mRNA has been ob-
served12 and suggested to result from a
reduced GH secretion or a reduced GH sensi-
tivity.13 The mechanisms regulating GH and
IGF levels in aged skeletal muscle are un-
known. A possible mechanism may be the cata-
bolic cytokine, tumor necrosis factor- (TNF),
which is increased in aging skeletal muscle.14
TNF and IGF-1 mRNA levels are increased
and decreased, respectively, in mouse skeletal
muscle following lipopolysaccharide injec-
tions, while the addition of TNF directly to
C2C12 mouse muscle cells also decreases 
IGF-1 mRNA.15 TNF is known to regulate the
transcription of suppressor of cytokine signal-
ing-3 (SOCS-3),16 with the latter able to inhibit
GH signaling to JAK2 and STAT5b.17,18 This
could possibly lead to a reduction in IGF
transcription. Whether SOCS-3 is increased and
the activation of the JAK/STAT pathway de-
creased in aged human skeletal muscle
is unknown.
A reduction in IGF-1 may also have a direct
effect on muscle hypertrophy and atrophy sig-
naling pathways as IGF-1 influences the acti-
vation of Akt (also known as protein kinase B
[PKB]). IGF-1 regulates the Akt/mTOR and the
Akt/GSK-3 signaling pathways, which are in-
volved in the skeletal muscle hypertrophy pro-
cess by activating downstream regulators of
protein initiation and translation.19 In the el-
derly when compared to younger subjects, a re-
duction on the total protein content of several
protein initiation and translation targets, such
as mTOR, p70s6k, 4E-BP1, and eIF2B, all of
which are either direct or indirect targets of
Akt,20–22 have been observed.23 Additionally,
the sensitivity and responsiveness of these pro-
teins to stimulation via administration of es-
sential amino acids are reduced in older sub-
jects.23 These results demonstrate that human
age-related sarcopenia is associated with a de-
crease in the content and sensitivity of several
proteins downstream of Akt, which are impli-
cated in catabolic processes. Inhibition of IGF-
1 to phosphorylate, and activate, Akt removes
the ability of Akt to phosphorylate, and inacti-
vate, the forkhead family of transcription fac-
tors (FKHR).24,25 The inhibition of Akt phos-
phorylation of FKHR allows FKHR nuclear
translocation where they have been shown, at
least in rodent muscle, to transcribe two mus-
cle-specific “atrogenes”––atrogin-1/MAFbx and
muscle ring finger-1 (MuRF1),24,25 which are in-
volved in the muscle atrophy process.26 A re-
duction in FKHR nuclear content in rodent
muscle is associated with a reduction in atro-
gin-1/MAFbx and MuRF1.24,25 At present it is
unknown if there is a perturbation in the ac-
tivity of Akt /FKHR signaling in human sar-
copenia.
Another interesting target, potentially mak-
ing a link between GH, IGF, and Akt signaling,
is myostatin. Myostatin, a member of the trans-
forming growth factor- family, inhibits mus-
cle development.27,28 Myostatin mRNA in el-
derly skeletal muscle has been shown to be
either increased29 or unchanged,12 when com-
pared to younger skeletal muscle, while myo-
statin protein levels in elderly muscle have not
been reported. Myostatin levels are inhibited
by GH in human muscle,30 suggesting that a
perturbation in GH levels, or GH activity, may
result in increased myostatin levels. It has re-
cently been reported that myostatin reduces the
activity of Akt in both cardiomyocytes31 and in
C2C12 cells where it also activates FKHR.32
Findings in the literature have prompted us
to hypothesize that human sarcopenia may be
linked to increased levels of in TNF and
SOCS-3 causing perturbations in GH signaling
and therefore increasing myostatin. Conse-
quently, this would result in a reduced activa-
tion of Akt signaling and therefore an inhibi-
tion and activation, respectively, of the muscle
hypertrophy and atrophy signaling cascades.
The aims of the present study were to deter-
mine if age-related sarcopenia in humans was
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linked with perturbations in TNF, SOCS-3,
GH, STAT5, and IGF levels, as well decreases
in the Akt/GSK/mTOR and increases in the
Akt/FKHR/atrogene signaling pathways.
METHODS AND MATERIALS
Subjects
Thirteen healthy males (age, 20  0.2 years;
body weight, 73.3  6.6 kg) and 16 older males
(age, 70  0.3 years; body weight, 78.0  8.5
kg) participated in the present study. All sub-
jects were healthy and active but were not
trained. The research protocol was approved
by the institutional ethics committee and in-
formed consent was obtained from all partici-
pants.
Muscle biopsies
All subjects agreed to a skeletal muscle bi-
opsy taken from the vastus lateralis muscles us-
ing a Bergstrom needle, as reported previ-
ously.33 All biopsies were immediately frozen
in liquid nitrogen and stored at 80°C until an-
alyzed.
Fiber size
Identification of type I, IIa, and IIx muscle
fiber types was performed using immunohis-
tochemical staining and their cross-sectional ar-
eas were measured, as previously described.34
RNA extraction and real-time quantitative PCR
RNA was extracted from skeletal muscle us-
ing a commercially available preparation, peq-
GOLD Tri-Fast (Peqlab, Erlangen, Germany).
Three g of RNA was reverse transcribed to
cDNA using Random Hexomer primers and a
Stratascript enzyme (Stratagene, Amsterdam,
The Netherlands) while quantitative PCR was
performed using the MX3000p thermal cycler
system, as published previously.35 PCR primer
and probe sequences (Stratagene, La Jolla, CA)
for atrogin-1, MuRF1, and ribosomal phospho-
protein PO (RPLPO; 36B4) have been reported
previously.35,36 Primers for TNF, SOCS-3, IGF-
1 and myostatin were forward, CG TCT CCT
ACC AGA CCA AGG; TTC AGC ATC TCT
GTC GGA AGA C; GTG GAG ACA GGG GCT
TTT ATT TC, AGG TAT ACT GGA ATC CGA
TCT CTG A and reverse, CC AAA GTA GAC
CTG CCC AGA; CGG CAG CTG GGT GAC
TTT; CTT GTT GTT TCC TGC ACT CCC TCT
ACT; CAC TGT CTT CAC ATC AAT GCT CTG.
Protein extraction and Western blot analysis
Cytosolic and nuclear proteins were ex-
tracted from 20 mg of skeletal muscle using
the NE-PER kit (Pierce, Rockford, IL) with the
addition of 2 L of PIC I, II, and III (Sigma, St.
Louis, MO). Electrophoresis was performed us-
ing 10–12% SDS PAGE gels in cold buffer (4°C)
containing 25 mM Tris (pH 8.8), 192 mM
glycine, and 10% methanol, as published pre-
viously.36 Conditions of incubation for Akt,
phospho-AktSer473, phospho-GSK-3Ser9, phos-
pho-4E-BP1Thr37/46, FKHR, FKHRL1, -tubu-
lin, and Lamin A have been published pre-
viously.35,36 The antibodies raised against
SOCS-3 and IGF-1 were from Santa Cruz
Biotechnology (Santa Cruz, CA); myostatin
from Biovendor (Modrice, Czech Republic);
STAT5, STAT5Tyr694, GSK-3, and 4E-BP1 from
Cell Signaling Technologies (Danvers, MA);
and GHR (MAB263) antibody from AbD
Serotec (Oxford, United Kingdom). All anti-
bodies were diluted 1:1000.
Statistical analysis
Unpaired t-tests were used to test for differ-
ences between the younger and older subjects.
The level of significance was set at p  0.05.
Data are mean  sem.
RESULTS
A representative immunohistological stain-
ing of a muscle cross section from a young and
older subject is presented in Figure 1A. The dif-
ferences in the cross-sectional area of type I, IIa,
and IIx fiber types are shown in Figure 1B. In
comparing the older with younger subjects, the
cross-sectional area of the type I muscle fibers
was 18% smaller, but this did not reach statis-
tical significance. However, the cross-sectional
area of type IIa and IIx muscle fiber was 40 and
45% smaller (p  0.01 and p  0.05, respec-
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tively). There was no statistical difference in the
percentage of type I, IIa, and IIx fiber types be-
tween groups.
In the skeletal muscle of the older compared
with the younger subjects, TNF, SOCS-3
mRNA, and SOCS-3 protein levels were in-
creased by 2.8, 1.5, and 1.5 fold, respectively (p 
0.05). Growth hormone receptor (GHR) protein
content was decreased by 45% (p  0.05). There
was no difference between STAT5 protein con-
tent; however, nuclear STAT5Tyr694 protein lev-
els tended to be increased by 1.4 fold in the mus-
cle of the older subjects, but this did not reach
statistical significance (p  0.056) (Fig. 2).
There was a significant (45%; p  0.05) re-
duction in IGF-1 mRNA in the older compared
with the younger subjects. This led us to de-
termine if this was paralleled with a reduction
in IGF-1 protein content, as well as several tar-
gets downstream of IGF-1 known to be in-
volved in muscle hypertrophy and atrophy.
There was no significant difference in IGF-1
protein levels between the older and younger
subjects. There was, however, a 2.5-fold in-
crease (p  0.05) in total Akt protein content in
the older compared with the younger subjects.
This did not result in an increase in the levels
of phosphorylated Akt (Fig. 3). However, when
determining the amount of phosphorylated ac-
tive Akt, relative to the total amount of Akt,
there was a 30% reduction (p  0.05) in the
older compared with the younger subjects.
GSK-3 and 4E-BP1 are downstream targets
of Akt, and regulators of protein initiation and
translation. In comparing the older with the
younger subjects, there was a 1.8-fold increase
(p  0.05) in total GSK-3 protein content,
which was paralleled by a 1.5-fold increase (p 
0.01) in phosphorylated GSK-3 protein levels.
When the ratio between phosphorylated and
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A
B
FIG. 1. Muscle cross-sectional area in young and old
subjects. (A) Identification of type I, IIa, and IIx muscle
fiber types using an immunohistochemical stain. Type I
fibers are stained green, type IIa fibers are stained blue,
while type IIx fibers are not stained. (B) A histogram de-
picting the changes in muscle fiber cross-sectional area
(CSA) of the young (black bars) and old (white bars) sub-
jects. Significantly different from young subjects (**p 
0.01; *p  0.05).
total GSK-3 protein levels was determined,
there was no significant difference between
groups. Total and phosphorylated 4E-BP1 pro-
tein levels were also not different between
groups (Fig. 4).
The FKHR family of transcription factors are
activated when Akt phosphorylation is re-
duced and can increase the transcription of
atrogin-1 and MuRF1, two genes involved in
muscle atrophy. Both FKHR (Foxo1) and
FKHRL1 (Foxo3) were decreased by 73% (p 
0.01) and 50% (p  0.05), respectively, in nu-
clear fractions from the older subjects, with no
changes in the mRNA levels of atrogin-1 and
MuRF1 (Fig. 5).
Myostatin, a negative regulator of muscle de-
velopment and inhibitor of Akt activity, was
also measured. Both myostatin mRNA and
protein levels were significantly elevated by 2.0
(p  0.05) and 1.4 fold (p  0.01), respectively,
in the muscle of the older subjects (Fig. 6).
For all mRNA analyses, the quantitative PCR
measurements for the genes of interest were
normalized to the housekeeping gene, riboso-
mal phosphoprotein PO (RPLPO; 36B4), which
remained stable across groups. The values for
the young and old subjects were 1.25  0.11
and 1.35  0.30 arbitrary units, respectively.
For protein measurement cytoplasmic and nu-
clear proteins were normalized to -tubulin
and Lamin A, respectively,36 which were sta-
ble across groups (online Supplementary Fig. 1
www.liebertonline.com/rej). Additionally,
the precision of protein loading was controlled
by performing a Ponceau stain for all mem-
branes. An example of a membrane with cyto-
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FIG. 2. Differences in the mRNA levels of TNF and SOCS-3 and protein
levels of SOCS-3, growth hormone receptor (GHR), phosphorylated
STAT5Tyr694, and total STAT5 in young and old subjects. The ratio of phos-
phorylated STAT5Tyr694 and total STAT5 is also shown. Significantly differ-
ent from young subjects (*p  0.05). The Western blot images are of three rep-
resentative young and old subjects.
plasmic and nuclear proteins is provided in
Supplementary Figure 2 (www.liebertonline.
com/rej). An example of several complete
Western blots is provided in Supplementary
Figure 3 (www.liebertonline.com/rej).
DISCUSSION
Age-related sarcopenia is associated with in-
creases in falls and fractures, which have an
important socioeconomic consequence as falls
are a major source of morbidity and mortality
in the increasing population of the elderly. The
mechanisms contributing to skeletal muscle at-
rophy are not well understood and the molec-
ular signaling pathways influencing sarcopenia
in humans have not been thoroughly inves-
tigated. Here we present several novel and
important findings showing that age-related
sarcopenia in older subjects compared with
younger ones reveals an increase in SOCS-3
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FIG. 3. Differences in the mRNA and protein levels of
IGF-1 and protein levels of total Akt and phosphorylated 
AktSer473. The ratio of phosphorylated AktSer473 and total
Akt is also shown. Significantly different from young sub-
jects (**p  0.01; *p  0.05). The Western blot images are
of three representative young and old subjects.
and myostatin mRNA and protein levels. There
were a reduced phosphorylation efficiency of
the total Akt pool and an increase in phosphor-
ylated GSK-3. Furthermore there was a de-
crease in FKHR and FKHRL1 nuclear protein
levels without changes in the mRNA levels of
their atrogene targets, atrogin-1 and MuRF1.
The GH/IGF-1 axis is a key regulator of an-
abolism8,19 and has been shown to be perturbed
in several models of muscle wasting, including
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FIG. 4. Differences in the protein levels of phosphorylated GSK-3Ser9 and 4E-BP1Thr37/46 total GSK-3 and 4E-BP1
in young and old subjects. The ratios of phosphorylated and total GSK-3 and phosphorylated and total 4E-BP1 are
also shown. Significantly different from young subjects (**p  0.01; *p  0.05). The Western blot images are of three
representative young and old subjects. 
sepsis, trauma, burns, AIDS, cancer, and renal
or liver failure,37–41 as well sarcopenia.42 In
HEK 293 cells, GHR signaling can be blocked
by SOCS-3 binding to the GHR,17 resulting in
the inhibition of JAK2/STAT5 mediated sig-
naling.18 Alternatively, SOCS-3 can also di-
rectly inhibit STAT5 activity.43,44 We therefore
hypothesized that perturbations in TNF/
SOCS-3/GHR signaling cascade may play a
key role in age-related human sarcopenia, via
the inhibition of JAK/STAT transcription of
IGF-1 mRNA. As observed previously,14 we
found a substantial increase in TNF mRNA in
older subjects, which was associated with an
increase in the TNF target gene SOCS-3 at
both the mRNA and protein levels. This in-
crease in SOCS-3 in human sarcopenia is sim-
ilar to that recently observed in old versus
young rats.45 We observed a tendency (p 
0.056) for an increase in the nuclear protein con-
tent of STAT5 in the older compared with the
younger subjects. STAT5 can be activated via
GHR signaling and inhibited by SOCS-3. In hu-
man sarcopenia, STAT5 may be activated, in a
GHR-independent manner, in an attempt to
offset a reduction in GHR sensitivity and re-
duce the amount of muscle loss. However, as
the STAT5 target gene IGF-1 was downregu-
lated, it appears that there may be a reduction
in transcriptional activity of STAT5 or that
other transcription factors may have a more
important regulatory role for IGF-1 mRNA in
elderly skeletal muscle. It has recently been ob-
served that serum response factor (SRF) can
also transcriptionally regulate IGF-1 mRNA in
muscle.46 Whether SRF does play a role in hu-
man sarcopenia remains to be elucidated, and
we are presently investigating this possibility.
Combined, these results suggest that GHR sen-
sitivity may be perturbed via a TNF/SOCS-3
mechanism that reduces IGF-1 mRNA tran-
scription.
Another key signaling pathway regulating
the maintenance of human skeletal muscle
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FIG. 5. Differences in the nuclear protein levels of FKHR and FKHRL1 and the mRNA expression of atrogin-1 and
MuRF1 in young and old subjects. Significantly different from young subjects (**p  0.01; *p  0.05). The Western
blot images are of three representative young and old subjects.
mass involves the IGF-1 phosphorylation and
activation of Akt, which initiates a series of sig-
naling cascades promoting protein synthesis19
and, in parallel, inhibits the transcription of
genes involved in protein degradation.24,25 Our
observation of a decrease in IGF-1 mRNA led
to the speculation that there would be a de-
crease in IGF and Akt protein levels in the older
compared to the younger subjects. There was
no significant decrease in IGF-1 protein, and
surprisingly there was an increase in total Akt
protein level. The increase in total Akt was not
associated with a concomitant increase in phos-
phorylated Akt levels in the older subjects. This
observation is novel and pertinent and indi-
cates the failed attempt of a potential mecha-
nism aimed at increasing protein synthesis
through providing more Akt protein. How-
ever, the inability of the older skeletal muscle
to phosphorylate more of the available Akt
pool demonstrates a reduced efficiency of Akt
phosphorylation. When expressed as the ratio
phosphorylated Akt/total Akt, there was a 30%
reduction in the older skeletal muscle. This ob-
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servation supports those recently made in older
rat skeletal muscle45 and suggests a reduced ef-
ficiency in skeletal muscle Akt phosphorylation
in elderly subjects.
Downstream targets of Akt involved in pro-
tein synthesis, 4E-BP1 and GSK-3,20,47 were
also measured. As the absolute amount of
phosphorylated Akt was the same between the
older and younger subjects, it would have been
expected that phosphorylated 4E-BP1 and
GSK-3 would also have been the same. As ex-
pected, no differences in the phosphorylation
levels of 4E-BP1 were observed. However,
there was an increase in the total protein con-
tent of GSK-3, which, unlike Akt, was paral-
leled by an increase in the phosphorylation
levels of GSK-3 in the older subjects. The in-
creased pool of GSK-3 protein may be a result
of increased protein translation or protein sta-
bility, aimed at providing the cell with a source
to maintain protein synthesis. The mechanisms
responsible for reducing the capacity to phos-
phorylate Akt appear not to influence GSK-3
phosphorylation, as increased levels of the lat-
ter were measured in the older subjects. These
observations also suggest the existence of a
mechanism that is able to phosphorylate GSK-
3, independently of Akt. A previous investi-
gation has observed an Akt-independent in-
crease in GSK-3 in mechanically stretched
rodent muscle.48 In line with this is the recent
suggestion that muscle protein synthesis rates
may be increased in a futile attempt to main-
tain muscle mass; however increased levels of
protein degradation is the determining factor
during sarcopenia.49 Sarcopenia, unlike severe
acute muscle-wasting disorders, such as ALS,
is a gradual process. This gradual loss of mus-
cle mass with age may be due to a number of
attempted “survival” feedback mechanisms,
including increases in the total pool of Akt and
GSK-3, as well as GSK-3 phosphorylation.
It has been demonstrated in rodents and my-
otubes that a reduced phosphorylation of Akt
also results in an increase in the nuclear con-
tent of the FKHR and FKHRL1 transcription
factors, as well as an increase in the expression
of their target genes, atrogin-1 and MuRF1, two
muscle-specific E3-ligases involved in protein
degradation.24,25,50 However, in the present
study, both FKHR and FKHRL1 nuclear pro-
tein levels were reduced in the skeletal muscle
of older compared to the younger subjects, sug-
gesting that factors other that Akt may be reg-
ulating human FKHR and FKHRL activities.
This is not without precedent as we36,51 and
others52 have previously observed that human
Akt and FKHR and FKHRL do not always fol-
low the same regulatory patterns. As FKHR
and FKHRL1 have been shown to regulate the
atrogin-1 and MuRF1 genes, at least in rodents,
this would suggest that the older subjects may
have a reduction in the gene expression of these
two atrophy genes. However, no differences in
the mRNA levels of atrogin-1 and MuRF1 were
observed between the two groups, which sup-
ports previous observations in aging human
skeletal muscle.53,54 This suggests that other
transcription factors may be involved in regu-
lating human atrogin-1 and MuRF1.35,36
A reduction in the efficiency to phosphory-
late Akt, observed in the present study and by
others in rodents,45 may be a crucial factor in
controlling sarcopenia. Therefore identifying
the factor(s) that may inhibit Akt phosphory-
lation is of importance. One such factor may be
myostatin, which has recently been reported to
reduce Akt phosphorylation in both cardiomy-
ocytes31 and in mouse C2C12 cells.32 Myostatin
mRNA, but not protein, levels have been
measured and compared previously in older
versus younger skeletal muscle, with investi-
gations showing either increases in older sub-
jects29 or no difference12 when compared to
younger subjects. However, it was deemed rel-
evant to measure the myostatin mRNA and
protein levels in the present study and to de-
termine if an association existed with Akt phos-
phorylation levels. Both myostatin mRNA and
protein levels were increased in the older com-
pared with younger subjects.
Although it is not within the scope of the
present study to establish a cause and effect re-
lationship between myostatin and Akt phos-
phorylation in human sarcopenia, these results,
in combination with those from Morissette et
al.31 and McFarlane et al.,32 suggest that ele-
vated myostatin levels may contribute to a re-
duced efficiency of Akt phosphorylation and
human age- related muscle loss.
The present study has focused on the poten-
tial perturbation of key signaling proteins that
may be involved in the reduction of muscle
mass in age-related sarcopenia. However, it is
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important to realize that there are other abnor-
malities occurring in aged skeletal muscle.
Other common phenotypical traits include, but
are not limited to, increased intramuscular
triglyceride (IMTG) accumulation,55,56 insulin
resistance,57 and a reduced myofiber regenera-
tive potential.58 Although these factors were
not measured in the present study, it is worth
mentioning that several of the novel observa-
tions made in the present study may be rele-
vant to these additional age- associated muscle
alterations. For example, SOCS-3 is also impli-
cated in triglyceride storage via its activation
of sterol regulatory element binding protein
(SREBP)-159 and can also cause insulin resis-
tance through downregulation of tyrosine
phosphorylation of insulin receptor substrate
(IRS) proteins.60 The reduced efficiency of Akt
phosphorylation is also linked to increased
IMTGs.61 The increase in skeletal muscle myo-
statin protein levels may be linked with myo-
fiber necrosis, as myostatin levels have been
shown to be elevated within necrotic, but not
regenerating fibers.62 Additionally, increased
levels of myostatin may contribute to reduced
myofiber regenerative potential58 by inhibiting
myoblast proliferation.63 Future investigations
should be aimed at establishing if the alter-
ations in signaling proteins observed in the
present study are also implicated in other ab-
normalities occurring in aged skeletal muscle.
In summary, this is the first study to com-
pare the regulation of several key signaling
pathways known to control skeletal muscle
hypertrophy, including GH/STAT5, IGF-1/
Akt/GSK/4E-BP1, and skeletal muscle atro-
phy, including TNF/SOCS-3 and Akt/FKHR/
atrogene, in muscle biopsies from young and
old men (Fig. 7). It appears that human sar-
copenia is associated with an increase in TNF
and SOCS-3, which may result in a reduction
of GHR levels or sensitivity. The significant in-
crease in total Akt protein content, but not Akt
phosphorylation in muscle from the older sub-
jects, suggests an inefficiency in Akt activation
and, by analogy, reduced protein synthesis.
The observed increase in myostatin mRNA and
protein levels in the older subjects, combined
with recent observations in cardiac and rodent
cells, suggest that myostatin is a prime candi-
date inhibiting Akt phosphorylation. Estab-
lishing if this is the case should be a priority
for future investigations aimed at reducing hu-
man sarcopenia.
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Supplementary FIG 1. Western blot analysis showing the stability of -tubulin in cytoplasmic
fractions and Lamin A in nuclear fractions.
Supplementary FIG 2. A Ponceau stain of membranes with cytoplasmic or nuclear proteins
demonstrating the accuracy of protein loading.
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Supplementary FIG 3. Examples of two complete Western blots.
